Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.
Borgogna C, De Andrea M, Griffante G, Lai A, Bergna A, Galli M, Zehender G, Castello L, Ravanini P, Cattrini C, Mennitto A, Gennari A, Gariglio M. Borgogna C, et al. Among authors: gariglio m. J Med Virol. 2021 Dec;93(12):6444-6446. doi: 10.1002/jmv.27200. Epub 2021 Jul 20. J Med Virol. 2021. PMID: 34260066 Free PMC article. No abstract available.
Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
Griffante G, Chandel S, Ferrante D, Caneparo V, Capello D, Bettio V, Borgogna C, Aleni C, Esposito S, Sarro A, Vasile A, Comba M, Testa T, Cotrupi G, De Andrea M, Bortoluzzi S, Gariglio M. Griffante G, et al. Among authors: gariglio m. Viruses. 2021 Nov 12;13(11):2270. doi: 10.3390/v13112270. Viruses. 2021. PMID: 34835076 Free PMC article.
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.
Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, Patriarca A, Mahmoud AM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Borgogna C, et al. Among authors: gariglio m. Blood Cancer J. 2022 Jan 18;12(1):8. doi: 10.1038/s41408-022-00608-6. Blood Cancer J. 2022. PMID: 35042847 Free PMC article. Clinical Trial.
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients.
Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, Patriarca A, Mahmoud AM, Ucciero MAM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Borgogna C, et al. Among authors: gariglio m. Br J Haematol. 2022 Nov;199(3):463-467. doi: 10.1111/bjh.18429. Epub 2022 Sep 5. Br J Haematol. 2022. PMID: 36062472 Free PMC article. No abstract available.
Cancer-Associated Fibroblasts Exert Proangiogenic Activity in Merkel Cell Carcinoma.
Albertini S, Martuscelli L, Borgogna C, Virdi S, Indenbirken D, Lo Cigno I, Griffante G, Calati F, Boldorini R, Fischer N, Gariglio M. Albertini S, et al. Among authors: gariglio m. J Invest Dermatol. 2023 Jun;143(6):965-976.e15. doi: 10.1016/j.jid.2022.12.006. Epub 2022 Dec 24. J Invest Dermatol. 2023. PMID: 36572089
PAD-mediated citrullination is a novel candidate diagnostic marker and druggable target for HPV-associated cervical cancer.
Albano C, Biolatti M, Mazibrada J, Pasquero S, Gugliesi F, Lo Cigno I, Calati F, Bajetto G, Riva G, Griffante G, Landolfo S, Gariglio M, De Andrea M, Dell'Oste V. Albano C, et al. Among authors: gariglio m. Front Cell Infect Microbiol. 2024 Mar 11;14:1359367. doi: 10.3389/fcimb.2024.1359367. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38529474 Free PMC article.
177 results